Invivyd shares are trading lower after the company announced topline data from the LIBERTY Phase 3, randomized, double-blind, active-controlled study evaluating the safety and tolerability of VYD2311.

Benzinga Newsdesk www.benzinga.com Negative 96.8%

Neg 96.8% Neu 0% Pos 0%

Comments

No comments yet. Be the first!